AbbVie Inc. Operating Cash Flow
AbbVie Inc. (ABBV) reported Operating Cash Flow of $7.26 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- AbbVie Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $3.44B, a 33.32% decline year-over-year.
- AbbVie Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $3.83B, a 134.19% increase year-over-year.
- AbbVie Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $5.22B, a 25.96% decline year-over-year.
- AbbVie Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $7.02B, a 28.95% increase year-over-year.
- AbbVie Inc. net cash provided by (used in) operating activities for fiscal 2025 was $19.03B, a 1.19% increase from fiscal 2024.
- AbbVie Inc. net cash provided by (used in) operating activities for fiscal 2024 was $18.81B, a 17.66% decline from fiscal 2023.
- AbbVie Inc. net cash provided by (used in) operating activities for fiscal 2023 was $22.84B, a 8.44% decline from fiscal 2022.
- AbbVie Inc. net cash provided by (used in) operating activities for fiscal 2022 was $24.94B, a 9.51% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.44B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $7.26B 10-Q · filed 2026-08-03 | $12.48B derived: sum of 3 quarters · filed 2026-08-03 | $19.51B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $3.83B 10-Q · filed 2026-05-08 | $9.05B derived: sum of 2 quarters · filed 2026-05-08 | $16.07B derived: sum of 3 quarters · filed 2026-05-08 | $21.22B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $5.22B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $12.24B derived: sum of 2 quarters · filed 2026-02-20 | $17.39B derived: sum of 3 quarters · filed 2026-08-03 | $19.03B 10-K · filed 2026-02-20 |
| 2025-09-30 | $7.02B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.18B derived: sum of 2 quarters · filed 2026-08-03 | $13.81B 10-Q · filed 2025-11-04 | $20.86B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $5.15B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $6.79B 10-Q · filed 2026-08-03 | $13.84B derived: sum of 3 quarters · filed 2026-08-03 | $19.28B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.64B 10-Q · filed 2026-05-08 | $8.68B derived: sum of 2 quarters · filed 2026-05-08 | $14.13B derived: sum of 3 quarters · filed 2026-05-08 | $16.40B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $7.05B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $12.49B derived: sum of 2 quarters · filed 2026-02-20 | $14.77B derived: sum of 3 quarters · filed 2026-02-20 | $18.81B 10-K · filed 2026-02-20 |
| 2024-09-30 | $5.45B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.72B derived: sum of 2 quarters · filed 2025-11-04 | $11.76B 10-Q · filed 2025-11-04 | $16.51B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $2.27B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $6.31B 10-Q · filed 2025-08-04 | $11.06B derived: sum of 3 quarters · filed 2026-02-20 | $18.64B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $4.04B 10-Q · filed 2025-05-09 | $8.79B derived: sum of 2 quarters · filed 2026-02-20 | $16.37B derived: sum of 3 quarters · filed 2026-02-20 | $22.69B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $4.75B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $12.33B derived: sum of 2 quarters · filed 2026-02-20 | $18.65B derived: sum of 3 quarters · filed 2026-02-20 | $22.84B 10-K · filed 2026-02-20 |
| 2023-09-30 | $7.57B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $13.89B derived: sum of 2 quarters · filed 2024-11-04 | $18.09B 10-Q · filed 2024-11-04 | $25.51B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $6.32B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $10.51B 10-Q · filed 2024-08-07 | $17.94B derived: sum of 3 quarters · filed 2025-02-14 | $25.54B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $4.19B 10-Q · filed 2024-05-03 | $11.62B derived: sum of 2 quarters · filed 2025-02-14 | $19.22B derived: sum of 3 quarters · filed 2025-02-14 | $24.23B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $7.43B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $15.03B derived: sum of 2 quarters · filed 2025-02-14 | $20.04B derived: sum of 3 quarters · filed 2025-02-14 | $24.94B 10-K · filed 2025-02-14 |
| 2022-09-30 | $7.60B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $12.61B derived: sum of 2 quarters · filed 2023-11-06 | $17.52B 10-Q · filed 2023-11-06 | $22.59B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $9.91B 10-Q · filed 2023-08-07 | $14.99B derived: sum of 3 quarters · filed 2024-02-20 | $22.92B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $4.91B 10-Q · filed 2023-05-05 | $9.98B derived: sum of 2 quarters · filed 2024-02-20 | $17.92B derived: sum of 3 quarters · filed 2024-02-20 | $22.81B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $5.08B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $13.01B derived: sum of 2 quarters · filed 2024-02-20 | $17.90B derived: sum of 3 quarters · filed 2024-02-20 | $22.78B 10-K · filed 2024-02-20 |
| 2021-09-30 | $7.93B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $12.82B derived: sum of 2 quarters · filed 2022-11-04 | $17.70B 10-Q · filed 2022-11-04 | $22.56B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $4.89B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.77B 10-Q · filed 2022-08-04 | $14.62B derived: sum of 3 quarters · filed 2023-02-17 | $20.45B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $4.88B 10-Q · filed 2022-05-06 | $9.73B derived: sum of 2 quarters · filed 2023-02-17 | $15.56B derived: sum of 3 quarters · filed 2023-02-17 | $18.65B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $4.85B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $10.68B derived: sum of 2 quarters · filed 2023-02-17 | $13.77B derived: sum of 3 quarters · filed 2023-02-17 | $17.59B 10-K · filed 2023-02-17 |
| 2020-09-30 | $5.83B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $8.92B derived: sum of 2 quarters · filed 2021-11-02 | $12.73B 10-Q · filed 2021-11-02 | $16.01B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $3.09B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $6.90B 10-Q · filed 2021-08-02 | $10.18B derived: sum of 3 quarters · filed 2022-02-18 | $14.73B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $3.81B 10-Q · filed 2021-05-07 | $7.09B derived: sum of 2 quarters · filed 2022-02-18 | $11.64B derived: sum of 3 quarters · filed 2022-02-18 | $14.12B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $3.27B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $7.83B derived: sum of 2 quarters · filed 2022-02-18 | $10.31B derived: sum of 3 quarters · filed 2022-02-18 | $13.32B 10-K · filed 2022-02-18 |
| 2019-09-30 | $4.55B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $7.03B derived: sum of 2 quarters · filed 2020-11-04 | $10.05B 10-Q · filed 2020-11-04 | $13.44B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $2.48B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $5.49B 10-Q · filed 2020-08-04 | $8.89B derived: sum of 3 quarters · filed 2021-02-19 | $13.41B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $3.02B 10-Q · filed 2020-05-08 | $6.41B derived: sum of 2 quarters · filed 2021-02-19 | $10.93B derived: sum of 3 quarters · filed 2021-02-19 | $13.80B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $3.39B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $7.92B derived: sum of 2 quarters · filed 2021-02-19 | $10.78B derived: sum of 3 quarters · filed 2021-02-19 | $13.43B 10-K · filed 2021-02-19 |
| 2018-09-30 | $4.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $7.39B derived: sum of 2 quarters · filed 2019-11-06 | $10.04B 10-Q · filed 2019-11-06 | $12.62B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $2.87B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $5.51B 10-Q · filed 2019-08-05 | $8.10B derived: sum of 3 quarters · filed 2020-02-21 | $11.37B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $2.65B 10-Q · filed 2019-05-03 | $5.23B derived: sum of 2 quarters · filed 2020-02-21 | $8.50B derived: sum of 3 quarters · filed 2020-02-21 | $10.50B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $2.58B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $5.86B derived: sum of 2 quarters · filed 2020-02-21 | $7.86B derived: sum of 3 quarters · filed 2020-02-21 | $9.96B 10-K · filed 2020-02-21 |
| 2017-09-30 | $3.27B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $5.27B derived: sum of 2 quarters · filed 2018-11-07 | $7.38B 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $2.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.11B 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $2.10B 10-Q · filed 2018-05-04 | |||
| 2016-09-30 | $1.45B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.37B derived: sum of 2 quarters · filed 2017-11-07 | $5.50B 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $1.92B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $4.05B 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $2.13B 10-Q · filed 2017-05-05 | |||
| 2015-09-30 | $5.57B 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |